Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cytokinetics

37.63
-0.7100-1.85%
Volume:799.97K
Turnover:30.57M
Market Cap:4.50B
PE:-7.35
High:39.12
Open:38.37
Low:37.58
Close:38.34
52wk High:59.39
52wk Low:29.31
Shares:119.66M
Float Shares:119.09M
Volume Ratio:0.66
T/O Rate:0.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.1182
EPS(LYR):-5.2646
ROE:-572.15%
ROA:-24.87%
PB:-12.21
PE(LYR):-7.15

Loading ...

Company Profile

Company Name:
Cytokinetics
Exchange:
NASDAQ
Establishment Date:
1997
Employees:
498
Office Location:
350 Oyster Point Boulevard,South San Francisco,California,United States
Zip Code:
94080
Fax:
- -
Introduction:
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Directors

Name
Position
John T. Henderson
Chairman
Robert I. Blum
Director,President and Chief Executive Officer
B. Lynne Parshall
Director
Edward M. Kaye
Director
James M. Daly
Director
Muna Bhanji
Director
Nancy J. Wysenski
Director
Robert A. Harrington
Director
Robert E. Landry
Director
Wendell Wierenga
Director

Shareholders

Name
Position
Robert I. Blum
Director,President and Chief Executive Officer
Sung H. Lee
Executive Vice President and Chief Financial Officer
Andrew M. Callos
Executive Vice President and Chief Commercial Officer
Fady I. Malik
Executive Vice President, Research and Development